BIIB - Company ID 0000875045
The table below shows BIOGEN INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.80B | $2.74B | $2.48B | $2.53B | $2.65B | $2.43B |
| Cost of revenue | $748.40M | $776.90M | $661.00M | $674.40M | $605.00M | $629.30M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
BIOGEN INC. reported annual revenue of $9.89B for fiscal year 2025. That is up 2.2% from $9.68B in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $11.45B (FY 2016) to $9.89B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $752.00M |
| $709.70M |
| $607.30M |
| $594.80M |
| $583.80M |
| $572.50M |
| Operating income | - | - | - | - | - | - |
| Income tax | $11.60M | $34.90M | $58.20M | $90.80M | $109.20M | $70.70M |
| Net income | -$20.60M | $97.50M | $319.50M | $466.50M | $634.80M | $240.50M |
| EPS (diluted) | -$0.14 | $0.66 | $2.15 | $3.17 | $4.33 | $1.64 |